CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results
CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex
How this was made
The 30-second read
Why it matters
Earnings miss may trigger short‑covering or further sell‑offs; however, margin improvement and product diversification provide a modest upside narrative.
Market read
Micro‑cap earnings release with modest financial improvement but revenue decline; likely limited market impact.
What to watch
Potential upside from new product launches (48% of revenue) and upcoming regulatory updates in December.
Background
CV Sciences is an OTC‑listed consumer wellness company focused on hemp extracts. The Q3 2026 filing includes a legal settlement gain and cost reductions.
Ticker impact
CV Sciences reported Q3 2026 results with revenue down 7% YoY and positive adjusted EBITDA of $32k.
likely downward pressure as investors price in lower revenue and regulatory headwinds
Revenue decline and ongoing regulatory challenges suggest limited upside; the modest EBITDA improvement is unlikely to offset the top‑line weakness.
Market effects
Highlights continued pressure on the hemp‑derived wellness sector from federal regulation.
May affect other OTC wellness companies facing similar regulatory scrutiny.
Limited; primarily a micro‑cap US OTC issue.
Counterpoint
The positive adjusted EBITDA and margin expansion could signal a turnaround if regulatory environment eases.
Key entities
- ExecutiveJoseph Dowling
CEO of CV Sciences who commented on the Q3 results.




